May 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountane.pl
Global Rank
#4,708,713
1,916,994Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
39.64%
Pages per Visit
2.06
Avg Visit Duration
00:00:47
- Company
- - -
- Industry
- - -
Top 10 ane.pl Competitors
The Top 10 Sites Like ane.pl in May 2026 are ranked by their affinity to ane.pl in terms of keyword traffic, audience targeting, and market overlap
- Company
- - -
- Industry
- - -
Global Rank
#1,137,388
92,897Bounce Rate
40.33%
Pages per Visit
1.69
Avg Visit Duration
00:00:20
Similarity Score
100%Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
64.63%
Pages per Visit
1.91
Avg Visit Duration
00:01:41
Similarity Score
96%Dr. Mikhail Blagosklonny | Aging
- Company
- - -
- Industry
- - -
Global Rank
#394,571
38,735Bounce Rate
43.92%
Pages per Visit
1.69
Avg Visit Duration
00:00:50
Similarity Score
92%- Company
- Remedy Publications
- Industry
- Health > Medicine
Global Rank
#1,244,329
84,911Bounce Rate
44.41%
Pages per Visit
1.56
Avg Visit Duration
00:00:14
Similarity Score
88%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
83%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
79.68%
Pages per Visit
1.12
Avg Visit Duration
00:00:03
Similarity Score
76%the scientific journal acta scientiarum polonorum. oeconomia began publication in 2001. it was established and operates under the aegis of a consortium of polish agricultural universities.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
28.73%
Pages per Visit
1.93
Avg Visit Duration
00:00:13
Similarity Score
74%- Company
- Collège de France
- Industry
- Law and Government > Government
Bounce Rate
51.63%
Pages per Visit
2.49
Avg Visit Duration
00:01:40
Similarity Score
69%Got questions about running the 2027 TCS London Marathon for the National Autistic Society? Find answers on places, fundraising, training support and more.
Global Rank
#77,934
5,837Bounce Rate
57.4%
Pages per Visit
2.14
Avg Visit Duration
00:01:33
Similarity Score
67%ane.pl's top 5 competitors in May 2026 are: cellmolbiol.org, jnm.snmjournals.org, aging-us.com, remedypublications.com, and more.
According to Similarweb data of monthly visits, ane.pl’s top competitor in May 2026 is cellmolbiol.org. ane.pl 2nd most similar site is jnm.snmjournals.org, and closing off the top 3 is aging-us.com.
remedypublications.com ranks as the 4th most similar website to ane.pl and klab.tch.harvard.edu ranks fifth in May 2026.
The other five competitors in the top 10 list are onlinebooks.library.upenn.edu, repec.iza.org, aspe.sggw.edu.pl, college-de-france.fr, and autism.org.uk.